Multienzyme Complexes Or Mixtures Of Enzymes Patents (Class 424/94.2)
-
Publication number: 20120230970Abstract: A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders.Type: ApplicationFiled: May 25, 2012Publication date: September 13, 2012Applicant: CUREMARK, LLCInventor: JOAN M. FALLON
-
Patent number: 8257694Abstract: A nutritional composition for reducing oxidative damage and lipid peroxidation in humans, while allowing for the oxidative reactions necessary to sustain vital biological functions. The nutritional compositions comprise adaptogens comprising astragalus root, ashwagandha root, cordyceps, holy basil leaf, maca root, reishi mushrooms, schisandra, and suma root; superfoods comprising acerola, camu-camu, pomegranate, bilberry, blueberry, Goji berries, Acai, maitake, citrus bioflavonoids, rose hips, and Gingko biloba; probiotics comprising Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus acidophilus DDS-1, Lactobacillus bulgaricus, Lactobacillus casei, and Streptococcus thermophilus; and enzymes comprising amylase, papain, cellulase, lactase, lipase, protease, and bromelain. The nutritional compositions may also be provided as a meal replacement and further comprise one or more plant products, algae, vitamins, minerals, protein and methylsulfonylmethane (MSM).Type: GrantFiled: May 14, 2009Date of Patent: September 4, 2012Assignee: Product Partners, LLCInventors: Carl D. Daikeler, Isabelle B. Daikeler, Darin L. Olien
-
Patent number: 8246951Abstract: The invention relates to a composition comprising at least one collagenolytic active enzyme with enzymatic activity at acidic pH for drilless enzymatic caries removal. Furthermore, the present invention relates to a process of producing this collagenolytic active enzyme comprising composition and to processes of removing caries. The invention also relates to the use of collagenolytic active enzyme comprising compositions for producing a treatment agent for dental applications.Type: GrantFiled: June 3, 2008Date of Patent: August 21, 2012Assignee: 3M Deutschland GmbHInventors: Oliver Kappler, Ingo R. Haeberlein
-
Publication number: 20120207732Abstract: Neural outgrowth in the central nervous system is achieved by administering chondroitinase AC and/or chondroitinase B to degrade chondroitin sulfate proteoglycans that inhibit or contribute to the inhibition of nervous tissue regeneration.Type: ApplicationFiled: April 20, 2012Publication date: August 16, 2012Inventors: Elliott A. GRUSKIN, Jennifer F. IACI, A. M. VECCHIONE, Sarah KASPERBAUER, Gargi ROY
-
Publication number: 20120195945Abstract: This invention is related to pharmacology and cosmetology and may be used in the capacity of a medicinal and cosmetic substance for skin anti-aging, scar reduction, treatment of post-operative peritoneal commissures, increasing the speed of post-operative tissue regeneration, and for the liquidation of cellulite.Type: ApplicationFiled: February 1, 2011Publication date: August 2, 2012Inventors: Artur Martynov, Boris S. Farber, Sonya Sophya Farber, Aleksandr Sitenko
-
Publication number: 20120177624Abstract: Disclosed is a disinfectant which is safe, has few adverse side-effects, can be ingested together with a food or beverage by adding the disinfectant to the food or beverage, shows a bactericidal effect in the oral cavity, and has no problem even when ingested on a daily basis over a long period. Also disclosed is a food additive comprising the disinfectant. Specifically, disclosed is an oral disinfectant for the disinfection of an oral bacterium, which comprises lactoperoxidase, glucose oxidase, glucose and a pH-adjusting component.Type: ApplicationFiled: March 22, 2012Publication date: July 12, 2012Applicant: MORINAGA MILK INDUSTRY CO., LTD.Inventors: Kouichirou Shin, Ayako Horigome, Koji Yamauchi
-
Publication number: 20120171187Abstract: The present invention relates to a debriding composition obtained from bromelain and to methods of producing same. Particularly, the present invention relates to a debriding composition obtained from bromelain comprising proteolytic enzymes having molecular weights of about 23 kDa, being essentially devoid of bromelain inhibitors, and to pharmaceutical compositions comprising same. The debriding compositions and the pharmaceutical compositions comprising same are particularly useful in debriding eschar tissues and in wound healing.Type: ApplicationFiled: February 6, 2012Publication date: July 5, 2012Inventors: Marian Gorecki, Amir Toren
-
Publication number: 20120148554Abstract: Administration of an exogenous pulmonary surfactant in combination with antioxidant enzymes is effective for the prevention of bronchopulmonary dysplasia (BPD) and decreases the markers of pulmonary oxidative stress.Type: ApplicationFiled: February 22, 2012Publication date: June 14, 2012Applicant: Chiesi Farmaceutici S.p.A.Inventor: Carlo DANI
-
Publication number: 20120134925Abstract: The present invention relates to the uses of the protein PRG4 and therapeutic modulation thereof. In particular, the present invention relates compositions and methods utilizing PRG4 and therapeutic modulation thereof, including, use as a surgical lubricant, use in a treatment for prevention or reduction of post-surgical adhesions, use in a treatment for oral ulcerations, use as an athletic lubricating patch, use as a dermal filler, use in a treatment for dry mouth, use in a drug delivery method or composition, and use in nursing lubrication.Type: ApplicationFiled: May 24, 2010Publication date: May 31, 2012Inventors: Benjamin Sullivan, Tannin Schmidt, Edward R. Truitt, Nicole Barbara Justis Truitt, David Sullivan
-
Publication number: 20120114626Abstract: A method of utilizing the chymotrypsin level of an individual as a measure of the success of neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders. A method for determining the efficacy of neuropeptides, peptides, or digestive enzymes for the treatment of an individual diagnosed with a pervasive developmental disorder (PDD) comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with neuropeptides, peptides, or digestive enzyme administration.Type: ApplicationFiled: December 7, 2011Publication date: May 10, 2012Applicant: CUREMARK, LLCInventor: Joan M. FALLON
-
Patent number: 8173120Abstract: The present invention relates to a method for substantially preventing a reduction in feed intake in an animal which occurs when said animal is administered an antibiotic, the method comprising administering to an animal in need of prevention of a reduction in feed intake, increasing doses of a composition comprising one or more antibiotics. The present invention also relates to a method for treating laminitis and fermentative acidosis in an animal in need of said treatment, the method comprising administering increasing doses of a composition comprising one or more antibiotics. The present invention further relates to a method for treating equine grass sickness and pulpy kidney in an animal in need of said treatment, the method comprising administering increasing doses of a composition comprising one or more antibiotics.Type: GrantFiled: December 15, 2006Date of Patent: May 8, 2012Assignee: Precision Nutrition Pty LtdInventors: James Baber Rowe, Christopher William Rowe
-
Publication number: 20120107296Abstract: The present invention relates to a feed supplement comprising a phytase and a lipolytic enzyme, wherein said lipolytic enzyme has lipase activity at a pH in the range of about pH1.5 to about pH3.5.Type: ApplicationFiled: April 23, 2010Publication date: May 3, 2012Applicant: DANISCO A/SInventors: Mai Faurschou Isaksen, Rikke Høegh Lorentsen, Peter Plumstead, Luis Fernando Romero Millán, Susan Madrid, Cherry Lin, Michael Ward, Masoud Rajabi Zargahi
-
Patent number: 8163278Abstract: A method of determining the efficacy of secretin, neuropeptides, peptides, and/or digestive enzymes for treatment of an individual diagnosed with a pervasive development disorder, such as autism, where the individual has an abnormal fecal chymotrypsin level and exhibits a lack of protein digestion. A sample of feces is obtained from the individual in order to determine a quantitative level of chymotrypsin in the sample. The quantitative level of chymotrypsin is used to determine the efficacy of treating the individual with secretin, neuropeptides, peptides, and/or digestive enzymes. If it is determined, based on the individual's fecal chymotrypsin level, that the individual would benefit from the administration of secretin, neuropeptides, peptides, and/or digestive enzymes, then the amount necessary to effect a change in the individual's autistic behavior is determined by the individual's fecal chymotrypsin level, age and weight.Type: GrantFiled: October 8, 2003Date of Patent: April 24, 2012Assignee: Curemark LLCInventor: Joan M. Fallon
-
Publication number: 20120093723Abstract: This invention provides multimeric nanocarrier for in vivo delivery of a bioactive agent, comprising at least two peptide monomers reversibly or irreversibly linked with one or more of said bioactive agents, wherein said two or more of said peptide monomers are covalently linked by a biodegradable difunctional moiety, as well as methods of using this nanocarrier.Type: ApplicationFiled: March 16, 2010Publication date: April 19, 2012Applicant: Rutgers, The State University of New JerseyInventors: Patrick J. Sinko, Stanley Stein, Simi Gunaseelan, Shahrair Pooyan, Matthew S. Palombo, Xiaoping Zhang
-
Publication number: 20120070504Abstract: A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.Type: ApplicationFiled: October 12, 2011Publication date: March 22, 2012Applicant: Curemark LLCInventor: Joan M. FALLON
-
Publication number: 20120070423Abstract: An oral composition for the treatment of dry mouth symptoms and other conditions, a method of forming the oral composition, and a method of using the oral composition are disclosed. The oral composition includes a plurality of enzymes to prevent formation of and/or facilitate the break up of biofilm in an oral cavity and a metal ion management system to inhibit growth of gram negative bacteria.Type: ApplicationFiled: April 26, 2011Publication date: March 22, 2012Inventor: Puneet Nanda
-
Patent number: 8119124Abstract: The present invention relates to a debriding composition obtained from bromelain and to methods of producing same. Particularly, the present invention relates to a debriding composition obtained from bromelain comprising proteolytic enzymes having molecular weights of about 23 kDa, being essentially devoid of bromelain inhibitors, and to pharmaceutical compositions comprising same. The debriding compositions and the pharmaceutical compositions comprising same are particularly useful in debriding eschar tissues and in wound healing.Type: GrantFiled: November 22, 2005Date of Patent: February 21, 2012Assignee: MediWound Ltd.Inventors: Marian Gorecki, Amir Toren
-
Patent number: 8105584Abstract: A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders. In one aspect, a method for determining the efficacy of secretin, other neuropeptides, peptides, or digestive enzymes for the treatment of an individual diagnosed with a pervasive developmental disorder (PDD) comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with secretin, other neuropeptides, peptides, or digestive enzyme administration.Type: GrantFiled: September 8, 2008Date of Patent: January 31, 2012Assignee: Curemark LLCInventor: Joan M. Fallon
-
Patent number: 8084236Abstract: Methods and compositions for modifying glycans (e.g., glycans expressed on the surface of live cells or cell particles) are provided herein.Type: GrantFiled: June 4, 2007Date of Patent: December 27, 2011Inventor: Robert Sackstein
-
Publication number: 20110300109Abstract: The present invention is based, in part, on our discovery of compositions and methods that can be used to systemically deplete arginine and thereby treat arginine-dependent cancers. Our studies indicate that administering a composition that depletes arginine directly to the patient's small intestine will provide effective treatment for arginine-dependent cancers. Moreover, the methods can be carried out in such a way that various sources of arginine are restricted and side effects are minimized. For example, to deplete arginine, one can not only administer an arginine-depleting enzyme directly to the intestinal lumen but can also inhibit endogenous production of arginine, reduce arginine production by intestinal bacteria and limit arginine intake. To minimize side effects, one can inhibit protein breakdown, which may occur as a compensatory mechanism, provide systemic NO from a nitric oxide donor, provide a pressor peptide, and/or provide prostacycline or an analog thereof.Type: ApplicationFiled: August 25, 2009Publication date: December 8, 2011Applicant: Kyon Biotech AGInventors: Slobodan Tepic, Goran Cvetkovic
-
Publication number: 20110300201Abstract: The invention provides methods, compositions, systems, and kits that include an enzyme/substrate co-delivery system. The liquid delivery system includes at least one enzyme encapsulated in a water-soluble polymeric matrix and a substrate for the enzyme in a carrier liquid in which the polymeric matrix is insoluble. When water is added, the polymeric matrix is solubilized and enzyme is released from the matrix, permitting catalytic action upon the substrate.Type: ApplicationFiled: November 3, 2009Publication date: December 8, 2011Applicant: DANISCO US INC.Inventors: Nathaniel T. Becker, Michael Stoner, Mee-Young Yoon
-
Patent number: 8071089Abstract: The invention provides compositions and methods for treating pancreatic enzyme insufficiency, such as the pancreatic enzyme insufficiency associated with cystic fibrosis. The invention also provides compositions comprising lipase from Candida cylindracea, alone or in combination with amylase or amyloglucosidase, protease and/or lactase. Furthermore, the invention discloses methods for treating pancreatic enzyme insufficiency comprising administering compositions to patients in need thereof.Type: GrantFiled: October 31, 2006Date of Patent: December 6, 2011Assignee: BIO-Cat, Inc.Inventors: Christopher Schuler, Edward Schuler
-
Publication number: 20110280853Abstract: Compositions and methods for treating or preventing S. aureus infections are provided. The compositions can be formulated as pharmaceutical compositions or as disinfectants, sanitizers, detergents or antiseptics, and can be used to eradicate or reduce S. aureus populations and thereby treat or prevent infection by S. aureus. The compositions include one or more digestive enzymes, e.g., one or more protease, lipases, and amylases. Methods of use of the compositions are also provided.Type: ApplicationFiled: January 6, 2010Publication date: November 17, 2011Inventors: Joan M. Fallon, Matthew Heil, James J. Fallon
-
Publication number: 20110280854Abstract: Compositions and methods for treating or preventing E. coli infections are provided. The compositions can be formulated as pharmaceutical compositions or as disinfectants, sanitizers, detergents or antiseptics, and can be used to eradicate or reduce E. coli populations and thereby treat or prevent infection by E. coli. The compositions include one or more digestive enzymes, e.g., one or more protease, lipases, and amylases. Methods of use of the compositions are also provided.Type: ApplicationFiled: January 6, 2010Publication date: November 17, 2011Inventors: Joan M. Fallon, Matthew Heil, James J. Fallon
-
Patent number: 8034766Abstract: The invention relates to compositions and methods for prion degradation, decontamination or disinfection. The composition comprises an oxidizing agent, one or more proteases and a surfactant such as an ionic surfactant/detergent. The method comprises contacting a prion contaminated entity with a prion-degrading composition comprising an effective amount of an oxidizing agent, an effective amount of at least one protease, and an effective amount of a surfactant. The components of the composition may be contacted with a prion-contaminated entity sequentially or simultaneously using an aqueous composition. Typically at least two different proteases are used for optimal efficacy. Preferably the oxidizing agent comprises peracetyl ions or a source thereof. The invention also relates to kits comprising the various reagents.Type: GrantFiled: October 26, 2007Date of Patent: October 11, 2011Assignees: E I du Pont de Nemours and Company, University College LondonInventors: Vincent Brian Croud, John Collinge, Graham Jackson
-
Publication number: 20110243908Abstract: A drug product comprising a combination of highly purified collagenase I and collagenase II from Colostridium histolyticum is disclosed. The drug product includes collagenase I and collagenase II in a ratio of about 1 to 1, with a purity of greater than at least 95%. The invention further disclosed improved fermentation and purification processes for preparing the said drug product.Type: ApplicationFiled: April 12, 2011Publication date: October 6, 2011Inventors: Gregory L. Sabatino, Benjamin J. Del Tito, JR., Phillip J. Bassett, Hazel A. Tharia, Antony G. Hitchcock
-
Publication number: 20110243909Abstract: A drug product comprising a combination of highly purified collagenase I and collagenase II from Colostridium histolyticum is disclosed. The drug product includes collagenase I and collagenase II in a ratio of about 1 to 1, with a purity of greater than at least 95%. The invention further disclosed improved fermentation and purification processes for preparing the said drug product.Type: ApplicationFiled: April 12, 2011Publication date: October 6, 2011Inventors: Gregory L. Sabatino, Benjamin J. Del Tito, JR., Phillip J. Bassett, Hazel A. Tharia, Antony G. Hitchcock
-
Publication number: 20110229598Abstract: The present invention relates to treatment of milk and milk products such as waste-milk with an enhanced lactoperoxidase system. The enhanced lactoperoxidase system is activated by the addition of a hydrogen peroxide source and an oxidizable agent, such as a halide to the milk to inactivate the bacterial pathogens. The enhanced lactoperoxidase system may be used alone or in conjunction with pasteurization to reduce or eliminate the bacterial load in milk products.Type: ApplicationFiled: March 11, 2011Publication date: September 22, 2011Applicant: Land O'Lakes Purina Feed LLCInventor: Robert C. Musser
-
Publication number: 20110223117Abstract: Isolated ?-glucanases from Hypocrea tawa, Trichoderma reesei, and Trichoderma konilangbra are described, as well as oral care compositions containing the same. The oral care composition may be employed to prevent or reduce dental plaque.Type: ApplicationFiled: April 9, 2009Publication date: September 15, 2011Inventors: Steven Kim, Suzanne Lantz, Michael Pepsin
-
Patent number: 8012930Abstract: A therapeutic method for treating an individual diagnosed with PDD pervasive developmental disorder comprises determining the efficacy of digestive enzyme administration for the treatment of the individual based on a measure of the individual's chymotrypsin level, and administering digestive enzymes to the individual based on the determination of the measure of the individual's chymotrypsin level. A method for reducing the amount of methylphenidate (Ritalin) being taken by an individual with attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) by administering a therapeutic amount of digestive enzymes is also provided.Type: GrantFiled: March 11, 2008Date of Patent: September 6, 2011Assignee: Curemark, LLCInventor: Joan M. Fallon
-
Patent number: 8013022Abstract: Disclosed is a multi-compartment medical device useful in the storage, processing and extended shelf life of perishable products, especially pharmaceutical, food and biological products. Particular biological materials processed according to the present methods are human blood and blood products (RBCs). Also disclosed are processes for preserving food, pharmaceutical and biological products for long-term storage and extended shelf life employing a process that reduces the hydration level of the material to less than native hydration levels of the specific product. The invention further provides stabilized biological products, such as in the form of glassified beads, prepared using a two-phase system according to the described processes that may be rehydrated and prepared for clinical use, and having essentially no loss of biological and/or pharmacological activity.Type: GrantFiled: April 27, 2007Date of Patent: September 6, 2011Inventors: Joseph DeAngelo, David Needham, Carroll Jones
-
Publication number: 20110200574Abstract: The present technology relates to an enzyme composition. The enzyme composition may be used to treat gluten intolerant subjects, including suffering from non-Celiac gluten intolerance and/or non-Celiac gluten sensitivity. The enzyme composition may also be used to reduce gluten exposure in certain individuals. For example, the enzyme composition may also be used as a prophylactic to reduce exposure to gluten oligopeptides.Type: ApplicationFiled: February 2, 2011Publication date: August 18, 2011Inventors: James F. Jolly, Hiroki Ido, Hirotaka Matsubara, Tetsuya Takahashi, Kyoichi Nishio
-
Publication number: 20110200575Abstract: Formulations are provided for the improvement of sleep patterns. The formulations generally include a trigger complex, an elemental complex and a coenzyme-vitamin B complex. The trigger complex is high in fiber such as glucomannan and includes Metallo-Lactoferrin protein in an alkaline buffer system. The elemental complex includes one or more trace element as a suitable salt. The coenzyme-vitamin B complex includes one or more coenzyme, coenzyme precursor and/or B-vitamin. The compositions may optionally include additional components such as 5-hydroxy-L-tryptophan (5-HTP), choline, melatonin, milk protein hydrolysate, L-arginine, and L-carnitine. The compositions can be administered orally in a variety of forms.Type: ApplicationFiled: April 28, 2011Publication date: August 18, 2011Applicant: Naidu LPInventors: A. Satyanarayan Naidu, A.G. Tezus Naidu, A.G. Sreus Naidu
-
Publication number: 20110195059Abstract: The invention provides methods, compositions, and kits for removal of biofilms from surfaces. The methods described herein comprise simultaneous or sequential application of a perhydrolase enzyme and a mixture of other enzymes, such as proteases, glucanases, esterases, mannanases, phospholipases, cellulases, and/or amylases, to a biofilm on a surface, to effect removal of the biofilm.Type: ApplicationFiled: December 16, 2008Publication date: August 11, 2011Applicant: DANISCO US INC.Inventors: Christopher C. Barnett, Manoj Kumar, Gregory M. Whited
-
Publication number: 20110189153Abstract: A drug product comprising a combination of highly purified collagenase I and collagenase II from Colostridium histolyticum is disclosed. The drug product includes collagenase I and collagenase II in a ratio of about 1 to 1, with a purity of greater than at least 95%. The invention further disclosed improved fermentation and purification processes for preparing the said drug product.Type: ApplicationFiled: April 12, 2011Publication date: August 4, 2011Inventors: Gregory L. Sabatino, Benjamin J. Del Tito, Phillip J. Bassett, Hazel A. Tharia, Antony G. Hitchcock
-
Publication number: 20110182874Abstract: Physiologically acceptable anti-biofilm compositions comprising Serratia peptidase and optionally one or more of bromelain, papain and a fibrinolytic enzyme. Additional components can include antimicrobials, antibiotics, antifungals, herbals, chelating agents, lactoferrin and related compounds, minerals, surfactants, binders, and fillers useful for the inhibition and treatment of gastrointestinal biofilms in humans. Physiologically acceptable anti-biofilm compositions containing these enzymes are useful in the inhibition, reduction and/or treatment of biofilms such as in the ear, vagina, joints, bones, gut, surgical sites and other locations, and are useful for the inhibition, reduction and/or treatment of associated systemic symptoms caused by biofilm associated microorganisms.Type: ApplicationFiled: March 25, 2011Publication date: July 28, 2011Applicant: PROTHERA, INC.Inventor: STEPHEN FRANCIS OLMSTEAD
-
Publication number: 20110182818Abstract: A therapeutic composition for the treatment of the symptoms of neurological and mental health disorders, such as Alzheimer's, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, and the method for preparing the therapeutic agents is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as an indicator of the presence of neurological and mental health disorders, such as Alzheimer's, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, or the likelihood of an individual to develop these disorders is disclosed.Type: ApplicationFiled: July 1, 2009Publication date: July 28, 2011Inventor: Joan M. Fallon
-
Publication number: 20110182873Abstract: Physiologically acceptable anti-biofilm compositions comprising Serratia peptidase and optionally one or more of bromelain, papain and a fibrinolytic enzyme. Additional components can include antimicrobials, antibiotics, antifungals, herbals, chelating agents, lactoferrin and related compounds, minerals, surfactants, binders, and fillers useful for the inhibition and treatment of gastrointestinal biofilms in humans. Physiologically acceptable anti-biofilm compositions containing these enzymes are useful in the inhibition, reduction and/or treatment of biofilms such as in the ear, vagina, joints, bones, gut, surgical sites and other locations, and are useful for the inhibition, reduction and/or treatment of associated systemic symptoms caused by biofilm associated microorganisms.Type: ApplicationFiled: March 25, 2011Publication date: July 28, 2011Applicant: PROTHERA, INC.Inventor: STEPHEN FRANCIS OLMSTEAD
-
Publication number: 20110177050Abstract: Physiologically acceptable anti-biofilm compositions comprising Serratia peptidase and optionally one or more of bromelain, papain and a fibrinolytic enzyme. Additional components can include antimicrobials, antibiotics, antifungals, herbals, chelating agents, lactoferrin and related compounds, minerals, surfactants, binders, and fillers useful for the inhibition and treatment of gastrointestinal biofilms in humans. Physiologically acceptable anti-biofilm compositions containing these enzymes are useful in the inhibition, reduction and/or treatment of biofilms such as in the ear, vagina, joints, bones, gut, surgical sites and other locations, and are useful for the inhibition, reduction and/or treatment of associated systemic symptoms caused by biofilm associated microorganisms.Type: ApplicationFiled: March 25, 2011Publication date: July 21, 2011Applicant: PROTHERA, INC.Inventor: Stephen Francis OLMSTEAD
-
Publication number: 20110177049Abstract: Physiologically acceptable anti-biofilm compositions comprising Serratia peptidase and optionally one or more of bromelain, papain and a fibrinolytic enzyme. Additional components can include antimicrobials, antibiotics, antifungals, herbals, chelating agents, lactoferrin and related compounds, minerals, surfactants, binders, and fillers useful for the inhibition and treatment of gastrointestinal biofilms in humans. Physiologically acceptable anti-biofilm compositions containing these enzymes are useful in the inhibition, reduction and/or treatment of biofilms such as in the ear, vagina, joints, bones, gut, surgical sites and other locations, and are useful for the inhibition, reduction and/or treatment of associated systemic symptoms caused by biofilm associated microorganisms.Type: ApplicationFiled: March 25, 2011Publication date: July 21, 2011Applicant: PROTHERA, INC.Inventor: Stephen Francis Olmstead
-
Publication number: 20110177048Abstract: Physiologically acceptable anti-biofilm compositions comprising Serratia peptidase and optionally one or more of bromelain, papain and a fibrinolytic enzyme. Additional components can include antimicrobials, antibiotics, antifungals, herbals, chelating agents, lactoferrin and related compounds, minerals, surfactants, binders, and fillers useful for the inhibition and treatment of gastrointestinal biofilms in humans. Physiologically acceptable anti-biofilm compositions containing these enzymes are useful in the inhibition, reduction and/or treatment of biofilms such as in the ear, vagina, joints, bones, gut, surgical sites and other locations, and are useful for the inhibition, reduction and/or treatment of associated systemic symptoms caused by biofilm associated microorganisms.Type: ApplicationFiled: March 25, 2011Publication date: July 21, 2011Applicant: PROTHERA, INC.Inventor: Stephen Francis Olmstead
-
Publication number: 20110171268Abstract: Compositions containing uricase are disclosed. Methods of treating a disorder associated with elevated uric acid concentrations using uricase are also described. Compositions containing uricase and catalase are also disclosed. Methods of treating a disorder associated with elevated uric acid concentrations using uricase and catalase are also described.Type: ApplicationFiled: March 24, 2009Publication date: July 14, 2011Applicant: Althea Technologies, Inc.Inventors: Bhami Shenoy, Danica Grujic, Reena Patel, Vinney George, Margaret Mcgrath, Nazer Khalaf, Emma Watson
-
Publication number: 20110171189Abstract: Physiologically acceptable anti-biofilm compositions comprising Serratia peptidase and optionally one or more of bromelain, papain and a fibrinolytic enzyme. Additional components can include antimicrobials, antibiotics, antifungals, herbals, chelating agents, lactoferrin and related compounds, minerals, surfactants, binders, and fillers useful for the inhibition and treatment of gastrointestinal biofilms in humans. Physiologically acceptable anti-biofilm compositions containing these enzymes are useful in the inhibition, reduction and/or treatment of biofilms such as in the ear, vagina, joints, bones, gut, surgical sites and other locations, and are useful for the inhibition, reduction and/or treatment of associated systemic symptoms caused by biofilm associated microorganisms.Type: ApplicationFiled: March 25, 2011Publication date: July 14, 2011Applicant: PROTHERA, INC.Inventor: STEPHEN FRANCIS OLMSTEAD
-
Publication number: 20110158972Abstract: A drug product comprising a combination of highly purified collagenase I and collagenase II from Clostridium histolyticum is disclosed. The drug product includes collagenase I and collagenase II in a ratio of about 1 to 1, with a purity of greater than at least 95%. The invention further disclosed improved fermentation and purification processes for preparing the said drug product.Type: ApplicationFiled: August 30, 2010Publication date: June 30, 2011Inventors: Gregory L. Sabatino, Benjamin J. Del Tito, JR., Phillip J. Bassett, Hazel A. Tharia, Antony G. Hitchcock
-
Publication number: 20110150855Abstract: Disclosed is a means effective for the treatment or prevention of inflammatory bowel disease. Specifically disclosed is an enzyme composition for the treatment or prevention of inflammatory bowel disease, which utilizes an enzyme capable of producing an oligosaccharide in vivo.Type: ApplicationFiled: January 21, 2008Publication date: June 23, 2011Applicants: Amano Enzyme Inc., Takashi Joh, Makoto SasakiInventors: Takashi Joh, Makoto Sasaki, Satoshi Koikeda
-
Publication number: 20110142756Abstract: The invention features compositions and methods for treating or alleviating a symptom of cancer. The compositions and methods of the invention direct supra-lethal doses of radiation, called Hot-Spots, to virtually all cancer cell types.Type: ApplicationFiled: October 4, 2010Publication date: June 16, 2011Inventors: George L. Mayers, Samuel Rose, David S. Rose
-
Publication number: 20110135621Abstract: The present invention relates generally to the field of treating bacterial infections. More particularly, it relates to an antimicrobial agent and methods of eliminating biofilm and planktonic cells using the antimicrobial agent.Type: ApplicationFiled: December 7, 2010Publication date: June 9, 2011Applicant: KCI LICENSING, INC.Inventors: Cynthia Miller, Amy Kathleen McNulty, Royce W. Johnson
-
Publication number: 20110129454Abstract: Physiologically acceptable anti-biofilm compositions comprising Serratia peptidase and optionally one or more of bromelain, papain and a fibrinolytic enzyme. Additional components can include antimicrobials, antibiotics, antifungals, herbals, chelating agents, lactoferrin and related compounds, minerals, surfactants, binders, and fillers useful for the inhibition and treatment of gastrointestinal biofilms in humans. Physiologically acceptable anti-biofilm compositions containing these enzymes are useful in the inhibition, reduction and/or treatment of biofilms such as in the ear, vagina, joints, bones, gut, surgical sites and other locations, and are useful for the inhibition, reduction and/or treatment of associated systemic symptoms caused by biofilm associated microorganisms.Type: ApplicationFiled: November 23, 2010Publication date: June 2, 2011Applicant: PROTHERA, INC.Inventor: STEPHEN FRANCIS OLMSTEAD
-
Publication number: 20110123633Abstract: Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing.Type: ApplicationFiled: February 2, 2011Publication date: May 26, 2011Applicant: EURAND PHARMACEUTICALS LTDInventors: Giovanni ORTENZI, Marco Marconi, Luigi Mapelli
-
Publication number: 20110123508Abstract: A composition or concentrate for cleaning medical or dental instruments comprising in combination a protease and a biostatically effective phenoxy alcohol such as phenoxyethanol selected such that at a working solution dilution of the combination, the phenoxy alcohol is at a concentration below the MIC of the selected phenoxy alcohol against Pseudomonas aeruginosa (ATCC 15442), and wherein the combination is nevertheless effective to reduce a 6 log concentration of Pseudomonas aeruginosa (ATCC 15442) by at least a 1 log concentration within 4 hours. The composition or concentrate may further include or more hydrolases and or boron or a boron compound. The composition may be used in methods for cleaning a soiled medical or dental instrument, for example in an ultrasonic bath.Type: ApplicationFiled: May 6, 2009Publication date: May 26, 2011Applicant: NOVAPHARM RESEARCH (AUSTRALIA) PTY. LTD.Inventors: Steven Kritzler, Alex Sava